Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease

"Phase 2 data reported at 2021 AD/PD Conference showed gamma frequency neuromodulation was safe and well tolerated
Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores as well as a significant 83% slowing in memory and cognitive decline as measured by MMSE scores compared to placebo/sham
Patients in the treatment group demonstrated a significant 61% reduction in whole brain atrophy and volumetric loss associated with AD, compared to placebo/sham at 6 months, demonstrating disease modification potential..." Lire la suite